lenticrispr v2 Search Results


lenticrispr v2  (Addgene inc)
96
Addgene inc lenticrispr v2
Lenticrispr V2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2/product/Addgene inc
Average 96 stars, based on 1 article reviews
lenticrispr v2 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
lenticrispr v2 blast vector  (Addgene inc)
96
Addgene inc lenticrispr v2 blast vector
Lenticrispr V2 Blast Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 blast vector/product/Addgene inc
Average 96 stars, based on 1 article reviews
lenticrispr v2 blast vector - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
lenticrispr v2 puro  (Addgene inc)
93
Addgene inc lenticrispr v2 puro
Lenticrispr V2 Puro, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 puro/product/Addgene inc
Average 93 stars, based on 1 article reviews
lenticrispr v2 puro - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
lenticrispr v2 vector  (Addgene inc)
93
Addgene inc lenticrispr v2 vector
Lenticrispr V2 Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 vector/product/Addgene inc
Average 93 stars, based on 1 article reviews
lenticrispr v2 vector - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
lenticrispr v2 h bak1  (Addgene inc)
93
Addgene inc lenticrispr v2 h bak1
(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / <t>BAK1</t> double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).
Lenticrispr V2 H Bak1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 h bak1/product/Addgene inc
Average 93 stars, based on 1 article reviews
lenticrispr v2 h bak1 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
sgrna targeting bap1  (Addgene inc)
93
Addgene inc sgrna targeting bap1
(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / <t>BAK1</t> double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).
Sgrna Targeting Bap1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sgrna targeting bap1/product/Addgene inc
Average 93 stars, based on 1 article reviews
sgrna targeting bap1 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
lenticrispr v2 hbax  (Addgene inc)
93
Addgene inc lenticrispr v2 hbax
(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / <t>BAK1</t> double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).
Lenticrispr V2 Hbax, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 hbax/product/Addgene inc
Average 93 stars, based on 1 article reviews
lenticrispr v2 hbax - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
plenticrispr cas9 v2 vector  (Addgene inc)
94
Addgene inc plenticrispr cas9 v2 vector
(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / <t>BAK1</t> double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).
Plenticrispr Cas9 V2 Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plenticrispr cas9 v2 vector/product/Addgene inc
Average 94 stars, based on 1 article reviews
plenticrispr cas9 v2 vector - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
lenticrisprv2-sgrna  (Qiagen)
90
Qiagen lenticrisprv2-sgrna
(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / <t>BAK1</t> double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).
Lenticrisprv2 Sgrna, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrisprv2-sgrna/product/Qiagen
Average 90 stars, based on 1 article reviews
lenticrisprv2-sgrna - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
lenticrisprv2  (Broad Institute Inc)
90
Broad Institute Inc lenticrisprv2
Plasmids.
Lenticrisprv2, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrisprv2/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
lenticrisprv2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
lenticrispr v2 plasmids  (GenScript corporation)
90
GenScript corporation lenticrispr v2 plasmids
Plasmids.
Lenticrispr V2 Plasmids, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 plasmids/product/GenScript corporation
Average 90 stars, based on 1 article reviews
lenticrispr v2 plasmids - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
crispr/cas9 expressing plasmid  (Amaxa)
90
Amaxa crispr/cas9 expressing plasmid
Plasmids.
Crispr/Cas9 Expressing Plasmid, supplied by Amaxa, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/crispr/cas9 expressing plasmid/product/Amaxa
Average 90 stars, based on 1 article reviews
crispr/cas9 expressing plasmid - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / BAK1 double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).

Journal: bioRxiv

Article Title: Atypical contribution of caspase-3 to melanoma cancer cell motility by regulation of coronin 1B activity

doi: 10.1101/2024.06.27.601010

Figure Lengend Snippet: (A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / BAK1 double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).

Article Snippet: 293T cells (1.5 x 10 6 cells in a 10-cm dish) were transfected with lentiCRISPR v2 h CASP3 (see plasmid construct part for design), lentiCRISPR v2 h BAX (Addgene, 129580) and/or LentiCRISPR v2 h BAK1 (Addgene, 129579) plasmids using Lipofectamine 2000.

Techniques: Western Blot, Expressing, Transfection, Concentration Assay, Control, Migration, CRISPR, Activation Assay, Knock-Out

Plasmids.

Journal: Molecular Biology of the Cell

Article Title: Lysosome docking to WIPI1 rings and ER-connected phagophores occurs during DNAJB12- and GABARAP-dependent selective autophagy of misfolded P23H-rhodopsin

doi: 10.1091/mbc.E21-10-0505

Figure Lengend Snippet: Plasmids.

Article Snippet: lentiCRISPRv2 , Feng Zhang, Broad Institute , 52961.

Techniques: